Compare Glenmark Pharma with KOPRAN. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs KOPRAN. - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA KOPRAN. GLENMARK PHARMA/
KOPRAN.
 
P/E (TTM) x 14.3 16.9 84.9% View Chart
P/BV x 2.1 3.7 56.2% View Chart
Dividend Yield % 0.5 0.7 67.3%  

Financials

 GLENMARK PHARMA   KOPRAN.
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
KOPRAN.
Mar-21
GLENMARK PHARMA/
KOPRAN.
5-Yr Chart
Click to enlarge
High Rs573146 391.2%   
Low Rs19522 902.1%   
Sales per share (Unadj.) Rs387.8113.7 341.1%  
Earnings per share (Unadj.) Rs34.414.2 241.4%  
Cash flow per share (Unadj.) Rs50.116.6 301.8%  
Dividends per share (Unadj.) Rs2.501.50 166.7%  
Avg Dividend yield %0.71.8 36.5%  
Book value per share (Unadj.) Rs249.656.7 440.6%  
Shares outstanding (eoy) m282.1743.25 652.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.00.7 134.0%   
Avg P/E ratio x11.25.9 189.3%  
P/CF ratio (eoy) x7.75.1 151.4%  
Price / Book Value ratio x1.51.5 103.7%  
Dividend payout %7.310.5 69.1%   
Avg Mkt Cap Rs m108,3533,634 2,981.5%   
No. of employees `000NANA-   
Total wages/salary Rs m23,437372 6,307.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m109,4394,918 2,225.2%  
Other income Rs m502182 276.7%   
Total revenues Rs m109,9415,100 2,155.9%   
Gross profit Rs m21,289816 2,608.5%  
Depreciation Rs m4,436102 4,352.0%   
Interest Rs m3,53162 5,659.8%   
Profit before tax Rs m13,825833 1,658.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,124217 1,897.8%   
Profit after tax Rs m9,701616 1,574.7%  
Gross profit margin %19.516.6 117.2%  
Effective tax rate %29.826.1 114.4%   
Net profit margin %8.912.5 70.8%  
BALANCE SHEET DATA
Current assets Rs m73,5962,769 2,657.4%   
Current liabilities Rs m42,0101,607 2,614.5%   
Net working cap to sales %28.923.6 122.1%  
Current ratio x1.81.7 101.6%  
Inventory Days Days75 121.6%  
Debtors Days Days86891 9.6%  
Net fixed assets Rs m67,0931,624 4,130.5%   
Share capital Rs m282433 65.2%   
"Free" reserves Rs m70,1482,018 3,476.5%   
Net worth Rs m70,4302,450 2,874.3%   
Long term debt Rs m38,888212 18,333.1%   
Total assets Rs m140,6894,394 3,202.0%  
Interest coverage x4.914.4 34.2%   
Debt to equity ratio x0.60.1 637.8%  
Sales to assets ratio x0.81.1 69.5%   
Return on assets %9.415.4 60.9%  
Return on equity %13.825.1 54.8%  
Return on capital %15.933.6 47.2%  
Exports to sales %040.5 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA1,990 0.0%   
Imports (cif) Rs mNA321 0.0%   
Fx inflow Rs m35,7531,990 1,796.2%   
Fx outflow Rs m12,023374 3,217.4%   
Net fx Rs m23,7291,617 1,467.7%   
CASH FLOW
From Operations Rs m11,312600 1,886.9%  
From Investments Rs m-6,752-244 2,766.6%  
From Financial Activity Rs m-4,418-346 1,277.9%  
Net Cashflow Rs m27810 2,859.2%  

Share Holding

Indian Promoters % 46.6 43.8 106.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 28.9 0.9 3,403.5%  
FIIs % 23.4 0.2 14,625.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 56.2 94.9%  
Shareholders   324,378 40,512 800.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   BETA DRUGS   AMRUTANJAN HEALTHCARE  SMRUTHI ORGANICS  CAPLIN POINT  ALPA LAB  



Today's Market

Sensex Slumps 700 Points from Day's High to End Lower; Tata Steel & SBI Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Sansera Engineering IPO: Key Points to Consider(Views On News)

Sep 8, 2021

This IPO is a pure OFS and the company is looking to raise Rs 12.8 bn at the upper price band of Rs 744.

5 Stocks that Turned Rs 1 Lakh into Rs 1 Crore(Views On News)

Sep 7, 2021

Patience is one of the biggest virtues you need to have if you want to become a crorepati in the stock market.

The Top Stocks to Sell in this Bull Market(Profit Hunter)

Sep 8, 2021

When I saw the list of so-called 'value stocks' published by a leading brokerage, my worst fears came true.

5 Indian Companies that are Leading the AI Race(Views On News)

Sep 9, 2021

During the pandemic, India reported the highest increase in the use of AI at 45% compared to other major economies. AI has potential to add US$90 bn to the Indian economy by 2025.

How to Create a Second Income from Trading(Profit Hunter)

Sep 10, 2021

My trading system that works in all kinds of markets.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2021
Get our special report Multibagger Stocks Guide (2021 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Sep 17, 2021 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS